Ausgabe 6/2023
Inhalt (11 Artikel)
Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Yoshitaka Honma, Masafumi Ikeda, Susumu Hijioka, Shigemi Matsumoto, Tetsuhide Ito, Taku Aoki, Junji Furuse
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation
Yujie Cui, Jinlong Liang, Xiyun Kang, Miaomiao Liu, Qi Zhang, Hongzhen Zhang
Antitumor activity of the new tyrphostin briva against BRAFV600E-mutant colorectal carcinoma cells
Khaled Saleh, Mai Al Sakhen, Sana Kanaan, Salem Yasin, Michael Höpfner, Lubna Tahtamouni, Bernhard Biersack
Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid
Miao Liu, Maoye Yuan, Wei Sun, Zuojun Li, Xingchen Zhou, Chunjiang Wang
Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1–3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial
Ting Deng, Le Zhang, Yehui Shi, Guiying Bai, Yueyin Pan, Aizong Shen, Xinghua Han, Zhaoyi Yang, Mingxia Chen, Hui Zhou, Yang Luo, Shirui Zheng, Yi Ba
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer
Lan Xu, Manyi Xu, Wei Sun, Weiping Zhang, Zhengbo Song
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial
Yuan Wu, Xuefeng Zhou, Weiqing Zhao, Qiong Wang, Zhengxiang Han, Lifeng Wang, Wenjie Zhou, Tong Zhou, Haizhu Song, Yong Chen, Kaihua Yang, Lin Shi, Banzhou Pan, Renhong Guo, Guoren Zhou, Feng Jiang, Jifeng Feng, Bo Shen
Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis
Chunjiang Wang, Wei Sun, Zuojun Li, Tian Wu, Weijin Fang
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines
Julia Schnoell, Carmen Sparr, Sega Al-Gboore, Markus Haas, Faris F. Brkic, Lorenz Kadletz-Wanke, Gregor Heiduschka, Bernhard J. Jank
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
Andrea Wang-Gillam, William Schelman, Stacey Ukrainskyj, Caly Chien, Martha Gonzalez, Zhao Yang, Marek Kania, Heather Yeckes-Rodin
Gastrointestinal signet ring cell malignancy: current advancement and future prospects
Weiping Hong, Qingjun Hu, Yuan Tan, Qianqian Duan, Qin Zhang, Dongsheng Chen, Chuang Qi, Da Wang